Fundraising Fox

Prexton Therapeutics

acquired by Lundbeck

Copenhagen, DK · 5 known investors

prextontherapeutics.com ↗

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.

BiotechHealthtechMedical Devices

Investors · 5

Cardinal PartnersPrinceton
M VenturesLos Angeles · $10.8M
Seroba Life SciencesDublin · $540K – $7.6M
Sunstone CapitalFrederiksberg
Ysios CapitalBarcelona · $5.4M – $21.6M

In the news

M&A of the Year: Prexton Therapeutics - Global Venturingglobalventuring.com · Jan 2019Newcomer Appello raises $10.5M for new Vanderbilt Parkinson’s drug | Fierce Biotechfiercebiotech.com · Jun 2018Lundbeck pounces for Prexton in $1.1bn acquisition - Global Venturingglobalventuring.com · Mar 2018Prexton Acquired by Lundbeck for up to €905m. – Seroba Lifesciencesserobavc.com · Mar 2018Serono spinout raises €29M for phase 2 Parkinson’s trials | Fierce Biotechfiercebiotech.com · Feb 2017Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round – Ysios Capitalysioscapital.com · Feb 2015Prexton Therapeutics Raises €8.7M in Series A Funding - FinSMEsfinsmes.com · Feb 2015

Frequently asked questions

What does Prexton Therapeutics do?
Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.
Who are Prexton Therapeutics's investors?
Prexton Therapeutics's investors include Cardinal Partners, M Ventures, Seroba Life Sciences, Sunstone Capital, Ysios Capital.
Who acquired Prexton Therapeutics?
Prexton Therapeutics was acquired by Lundbeck.
Where is Prexton Therapeutics headquartered?
Prexton Therapeutics is headquartered in Copenhagen, DK.